Incyclix Bio has reported outcomes from the dose escalation part of the Phase I/II INX-315-01 trial of INX-315 for breast cancer treatment.

The US FDA has granted clearance to SpliceBio’s IND application to begin the trial of SB-007, designed for Stargardt disease treatment.

The Phase I expansion Mythic trial saw a 25.9% overall response rate for endometrial cancer and 37.5% in platinum-resistant ovarian cancer.

Mesoblast Limited recently announced positive Phase III trial results in the European Journal of Heart Failure.

The WHO’s guidance provides direction on diversity and how to include patients who are pregnant, lactating and from low-middle income countries.

Trevi has announced that its Phase IIb trial of Haduvio in treating IPF subjects with chronic cough will continue without sample size change.

SK bioscience has gained Australia’s Human Research Ethics Committee (HREC) approval to begin Phase I/II clinical trials of GBP560.

Annual Meeting, held on 7-10 December, early results from the double-blind, randomised, placebo-controlled, Phase III inMIND clinical trial were presented.

The Phase I trial of the company’s SRSD107 siRNA therapy found the treatment to be safe and well tolerated in its first-in-human tests.

Satellos Bioscience has dosed the first subject with DMD in a Phase Ib trial of its oral small molecule drug candidate, SAT-3247.

Lisata Therapeutics has completed the enrolment of subjects for the CENDIFOX study of certepetide across multiple cancer types.

Creating contingency plans against geopolitical uncertainty was a key theme at the 2024 Outsourcing in Clinical Trials and Clinical Trial Supply East Asia conference in Seoul.